Targeting IgE production in mice and humans

Current Opinion in Immunology

Volumn 31, Issue 1, 2014, Pages 8-15

  Wu, Lawren C ^a   Scheerens, Heleen ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTRAKINCEPT; AMG 317; ANRUKINZUMAB; ANTIASTHMATIC AGENT; B LYMPHOCYTE RECEPTOR; DUPILUMAB; FC RECEPTOR IIB; GSK 67586; IMA 026; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G1; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR ALPHA; LEBRIKIZUMAB; PITRAKINRA; QUILIZUMAB; TRALOKINUMAB; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; IL4 PROTEIN, HUMAN; IL4RA PROTEIN, MOUSE;

ALLERGIC ASTHMA; ALLERGIC RHINITIS; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ASTHMA; B LYMPHOCYTE; DRUG TARGETING; GENE REARRANGEMENT; GERMINAL CENTER; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN PRODUCTION; IMMUNOLOGICAL MEMORY; MEMORY CELL; NONHUMAN; PLASMA CELL; REVIEW; ANIMAL; HYPERSENSITIVITY; IMMUNOLOGY; MOUSE; PATHOLOGY;

ANIMALS; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; IMMUNOLOGIC MEMORY; INTERLEUKIN-13; INTERLEUKIN-4; MICE; PLASMA CELLS; RECEPTORS, CELL SURFACE;

EID: 84906501429     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2014.08.001     Document Type: Review

References (55)

1. Gould H.J., Sutton B.J. IgE in allergy and asthma today. Nat Rev Immunol 2008, 8:205-217.
2. Kuhl K., Hanania N.A. Targeting IgE in asthma. Curr Opin Pulm Med 2012, 18:1-5.
3. Hochhaus G., Brookman L., Fox H., Johnson C., Matthews J., Ren S., Deniz Y. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin 2003, 19:491-498.
4. Punnonen J., Aversa G., Cocks B.G., McKenzie A.N., Menon S., Zurawski G., de Waal Malefyt R., de Vries J.E. Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells. Proc Natl Acad Sci U S A 1993, 90:3730-3734.
5. Zurawski G., de Vries J.E. Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol Today 1994, 15:19-26.
6. Achatz G., Nitschke L., Lamers M.C. Effect of transmembrane and cytoplasmic domains of IgE on the IgE response. Science 1997, 276:409-411.
7. Achatz-Straussberger G., Zaborsky N., Konigsberger S., Luger E.O., Lamers M., Crameri R., Achatz G. Migration of antibody secreting cells towards CXCL12 depends on the isotype that forms the BCR. Eur J Immunol 2008, 38:3167-3177.
8. Davies J.M., Platts-Mills T.A., Aalberse R.C. The enigma of IgE+ B-cell memory in human subjects. J Allergy Clin Immunol 2013, 131:972-976.
9. Dullaers M., De Bruyne R., Ramadani F., Gould H.J., Gevaert P., Lambrecht B.N. The who, where, and when of IgE in allergic airway disease. J Allergy Clin Immunol 2012, 129:635-645.
10. Wu L.C., Zarrin A.A. The production and regulation of IgE by the immune system. Nat Rev Immunol 2014, 14:247-259.
11. Yang Z., Robinson M.J., Allen C.D. Regulatory constraints in the generation and differentiation of IgE-expressing B cells. Curr Opin Immunol 2014, 28C:64-70.
12. Brightbill H.D., Jeet S., Lin Z., Yan D., Zhou M., Tan M., Nguyen A., Yeh S., Delarosa D., Leong S.R., et al. Antibodies specific for a segment of human membrane IgE deplete IgE-producing B cells in humanized mice. J Clin Invest 2010, 120:2218-2229.
13. Lafaille J.J., Xiong H., Curotto de Lafaille M.A. On the differentiation of mouse IgE(+) cells. Nat Immunol 2012, 13:623.
14. Talay O., Yan D., Brightbill H.D., Straney E.E., Zhou M., Ladi E., Lee W.P., Egen J.G., Austin C.D., Xu M., et al. IgE(+) memory B cells and plasma cells generated through a germinal-center pathway. Nat Immunol 2012, 13:396-404.
15. Talay O., Yan D., Brightbill H.D., Straney E.E., Zhou M., Ladi E., Lee W.P., Egen J.G., Austin C.D., Xu M., et al. Reply to "On the differentiation of mouse IgE(+) cells". Nat Immunol 2012, 13:623-624.
16. Talay O., Yan D., Brightbill H.D., Straney E.E., Zhou M., Ladi E., Lee W.P., Egen J.G., Austin C.D., Xu M., et al. Addendum: IgE(+) memory B cells and plasma cells generated through a germinal-center pathway. Nat Immunol 2013, 14:1302-1304.
17. He J.S., Meyer-Hermann M., Xiangying D., Zuan L.Y., Jones L.A., Ramakrishna L., de Vries V.C., Dolpady J., Aina H., Joseph S., et al. The distinctive germinal center phase of IgE+ B lymphocytes limits their contribution to the classical memory response. J Exp Med 2013, 210:2755-2771.
18. Yang Z., Sullivan B.M., Allen C.D. Fluorescent in vivo detection reveals that IgE(+) B cells are restrained by an intrinsic cell fate predisposition. Immunity 2012, 36:857-872.
19. Erazo A., Kutchukhidze N., Leung M., Christ A.P., Urban J.F., Curotto de Lafaille M.A., Lafaille J.J. Unique maturation program of the IgE response in vivo. Immunity 2007, 26:191-203.
20. Mota I. Biological characterization of mouse 'early' antibodies. Immunology 1967, 12:343-348.
21. Revoltella R., Ovary Z. Reaginic antibody production in different mouse strains. Immunology 1969, 17:45-54.
22. Holt P.G., Sedgwick J.D., O'Leary C., Krska K., Leivers S. Long-lived IgE- and IgG-secreting cells in rodents manifesting persistent antibody responses. Cell Immunol 1984, 89:281-289.
23. Luger E.O., Fokuhl V., Wegmann M., Abram M., Tillack K., Achatz G., Manz R.A., Worm M., Radbruch A., Renz H. Induction of long-lived allergen-specific plasma cells by mucosal allergen challenge. J Allergy Clin Immunol 2009, 124:819-826. e814.
24. Grunewald S.M., Werthmann A., Schnarr B., Klein C.E., Brocker E.B., Mohrs M., Brombacher F., Sebald W., Duschl A. An antagonistic IL-4 mutant prevents type I allergy in the mouse: inhibition of the IL-4/IL-13 receptor system completely abrogates humoral immune response to allergen and development of allergic symptoms in vivo. J Immunol 1998, 160:4004-4009.
25. Kasaian M.T., Tan X.Y., Jin M., Fitz L., Marquette K., Wood N., Cook T.A., Lee J., Widom A., Agostinelli R., et al. Interleukin-13 neutralization by two distinct receptor blocking mechanisms reduces immunoglobulin E responses and lung inflammation in cynomolgus monkeys. J Pharmacol Exp Ther 2008, 325:882-892.
26. Kuhn R., Rajewsky K., Muller W. Generation and analysis of interleukin-4 deficient mice. Science 1991, 254:707-710.
27. Noben-Trauth N., Shultz L.D., Brombacher F., Urban J.F., Gu H., Paul W.E. An interleukin 4 (IL-4)-independent pathway for CD4+ T cell IL-4 production is revealed in IL-4 receptor-deficient mice. Proc Natl Acad Sci U S A 1997, 94:10838-10843.
28. Katona I.M., Urban J.F., Kang S.S., Paul W.E., Finkelman F.D. IL-4 requirements for the generation of secondary in vivo IgE responses. J Immunol 1991, 146:4215-4221.
29. Brightbill H.D., Lin Y.L., Lin Z., Tan M., Meng Y.G., Balazs M., Chung S., Wu L.C. Quilizumab is an afucosylated humanized anti-M1 prime therapeutic antibody. Clin Anti-Inflamm Anti-Allergy Drugs 2014, 1:24-31.
30. Chen J.B., Wu P.C., Hung A.F., Chu C.Y., Tsai T.F., Yu H.M., Chang H.Y., Chang T.W. Unique epitopes on C epsilon mX in IgE-B cell receptors are potentially applicable for targeting IgE-committed B cells. J Immunol 2010, 184:1748-1756.
31. Chowdhury P.S., Chen Y., Yang C., Cook K.E., Nyborg A.C., Ettinger R., Herbst R., Kiener P.A., Wu H. Targeting the junction of CvarepsilonmX and varepsilon-migis for the specific depletion of mIgE-expressing B cells. Mol Immunol 2012, 52:279-288.
32. Chu H.M., Wright J., Chan Y.H., Lin C.J., Chang T.W., Lim C. Two potential therapeutic antibodies bind to a peptide segment of membrane-bound IgE in different conformations. Nat Commun 2014, 5:3139.
33. Chu S.Y., Horton H.M., Pong E., Leung I.W., Chen H., Nguyen D.H., Bautista C., Muchhal U.S., Bernett M.J., Moore G.L., et al. Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcgammaRIIb with Fc-engineered antibody. J Allergy Clin Immunol 2012, 129:1102-1115.
34. Feichtner S., Infuhr D., Achatz-Straussberger G., Schmid D., Karnowski A., Lamers M., Rhyner C., Crameri R., Achatz G. Targeting the extracellular membrane-proximal domain of membrane-bound IgE by passive immunization blocks IgE synthesis in vivo. J Immunol 2008, 180:5499-5505.
35. Haba S., Nisonoff A. Inhibition of IgE synthesis by anti-IgE: role in long-term inhibition of IgE synthesis by neonatally administered soluble IgE. Proc Natl Acad Sci U S A 1990, 87:3363-3367.
36. Haba S., Nisonoff A. Effects of syngeneic anti-IgE antibodies on the development of IgE memory and on the secondary IgE response. J Immunol 1994, 152:51-57.
37. Ota T., Aoki-Ota M., Duong B.H., Nemazee D. Suppression of IgE B cells and IgE binding to Fc(epsilon)RI by gene therapy with single-chain anti-IgE. J Immunol 2009, 182:8110-8117.
38. Grammer L.C., Zeiss C.R., Levitz D., Roberts M., Pruzansky J.J. Variation with season and with polymerized ragweed immunotherapy in IgE against ragweed antigen E in plasma and eluted from the basophil surface in patients with ragweed pollenosis. J Clin Immunol 1981, 1:222-227.
39. Johansson S.G., Bennich H., Berg T., Hogman C. Some factors influencing the serum IgE levels in atopic diseases. Clin Exp Immunol 1970, 6:43-47.
40. Yunginger J.W., Gleich G.J. Seasonal changes in IgE antibodies and their relationship to IgG antibodies during immunotherapy for ragweed hay fever. J Clin Invest 1973, 52:1268-1275.
41. Mitre E., Nutman T.B. IgE memory: persistence of antigen-specific IgE responses years after treatment of human filarial infections. J Allergy Clin Immunol 2006, 117:939-945.
42. Bellou A., Kanny G., Fremont S., Moneret-Vautrin D.A. Transfer of atopy following bone marrow transplantation. Ann Allergy Asthma Immunol 1997, 78:513-516.
43. Hallstrand T.S., Sprenger J.D., Agosti J.M., Longton G.M., Witherspoon R.P., Henderson W.R. Long-term acquisition of allergen-specific IgE and asthma following allogeneic bone marrow transplantation from allergic donors. Blood 2004, 104:3086-3090.
44. Gould H.J., Takhar P., Harries H.E., Durham S.R., Corrigan C.J. Germinal-centre reactions in allergic inflammation. Trends Immunol 2006, 27:446-452.
45. Corren J., Lemanske R.F., Hanania N.A., Korenblat P.E., Parsey M.V., Arron J.R., Harris J.M., Scheerens H., Wu L.C., Su Z., et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011, 365:1088-1098.
46. Noonan M., Korenblat P., Mosesova S., Scheerens H., Arron J.R., Zheng Y., Putnam W.S., Parsey M.V., Bohen S.P., Matthews J.G. Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids. J Allergy Clin Immunol 2013, 132:567-574. e512.
47. Scheerens H., Arron J.R., Zheng Y., Putnam W.S., Erickson R.W., Choy D.F., Harris J.M., Lee J., Jarjour N.N., Matthews J.G. The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge. Clin Exp Allergy 2014, 44:38-46.
48. De Boever E.H., Ashman C., Cahn A.P., Locantore N.W., Overend P., Pouliquen I.J., Serone A.P., Wright T.J., Jenkins M.M., Panesar I.S., et al. Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: a randomized trial. J Allergy Clin Immunol 2014, 133:989-996. e984.
49. Gauvreau G.M., Boulet L.P., Cockcroft D.W., Fitzgerald J.M., Carlsten C., Davis B.E., Deschesnes F., Duong M., Durn B.L., Howie K.J., et al. Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. Am J Respir Crit Care Med 2011, 183:1007-1014.
50. Borish L.C., Nelson H.S., Corren J., Bensch G., Busse W.W., Whitmore J.B., Agosti J.M. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 2001, 107:963-970.
51. Wenzel S., Wilbraham D., Fuller R., Getz E.B., Longphre M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007, 370:1422-1431.
52. Corren J., Busse W., Meltzer E.O., Mansfield L., Bensch G., Fahrenholz J., Wenzel S.E., Chon Y., Dunn M., Weng H.H., et al. A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med 2010, 181:788-796.
53. Wenzel S., Ford L., Pearlman D., Spector S., Sher L., Skobieranda F., Wang L., Kirkesseli S., Rocklin R., Bock B., et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013, 368:2455-2466.
54. Gauvreau G.M., Harris J.M., Boulet L.P., Scheerens H., Fitzgerald J.M., Putnam W.S., Cockcroft D.W., Davis B.E., Leigh R., Zheng Y., et al. Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production. Sci Transl Med 2014, 6. 243ra285.
55. Piper E., Brightling C., Niven R., Oh C., Faggioni R., Poon K., She D., Kell C., May R.D., Geba G.P., et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J 2013, 41:330-338.